Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Pharmaceutical Reviews Update — Issue 55

Details

Program Updates

1. Methods Guide Update

Canada’s Drug Agency  (CDA-AMC) has published our first-ever guidance document on health technology assessment (HTA) methods used in the appraisal of clinical evidence for a drug submitted by a sponsor to our drug reimbursement review program.  

Last Updated : February 27, 2025

vorasidenib

Details

Key Milestones2
Call for patient/clinician input open19-Mar-25
Call for patient/clinician input closed12-May-25
Submission received30-Apr-25
Submission accepted-
Last Updated : April 30, 2025

darolutamide

Details

Key Milestones2
Call for patient/clinician input open13-Mar-25
Call for patient/clinician input closed06-May-25
Submission received28-Apr-25
Clarification:

Eligible for review through the PACES process

Submission accepted-
Last Updated : April 29, 2025